1136642-15-3

Basic information

• Product Name: 1,6‐diamino‐4‐(2‐bromophenyl)‐2‐oxo‐1,2‐dihydropyridine‐3,5‐dicarbonitrile
• Synonyms: 1,6‐diamino‐4‐(2‐bromophenyl)‐2‐oxo‐1,2‐dihydropyridine‐3,5‐dicarbonitrile
• CAS NO: 1136642-15-3
• Molecular Weight: 330.143
• Mol File: 1136642-15-3.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 1,6‐diamino‐4‐(2‐bromophenyl)‐2‐oxo‐1,2‐dihydropyridine‐3,5‐dicarbonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 1,6‐diamino‐4‐(2‐bromophenyl)‐2‐oxo‐1,2‐dihydropyridine‐3,5‐dicarbonitrile(1136642-15-3)
• EPA Substance Registry System: 1,6‐diamino‐4‐(2‐bromophenyl)‐2‐oxo‐1,2‐dihydropyridine‐3,5‐dicarbonitrile(1136642-15-3)

Safety Data

• Hazardous Substances Data: 1136642-15-3(Hazardous Substances Data)

Upstream product

• 2698-42-2 2-(2-bromobenzylidene)malononitrile 
• 140-87-4 Cyanoacetohydrazide 
• 319429-81-7 N'‐(2‐bromobenzylidene)‐2‐cyanoacetohydrazide 
• 109-77-3 malononitrile 
• 6630-33-7 ortho-bromobenzaldehyde 

Downstream Products

• 1184722-03-9 C₂₀H₁₀BrN₅O 
• 1184722-04-0 C₂₀H₉BrClN₅O 
• 1184722-05-1 C₂₁H₁₂BrN₅O 
• 1184722-02-8 C₂₀H₉Br₂N₅O 

Relevant articles and documents

Pyridine-derived VEGFR-2 inhibitors: Rational design, synthesis, anticancer evaluations, in silico ADMET profile, and molecular docking

Novel pyridine-derived compounds (5–19) were designed and?synthesized, and their anticancer activities were evaluated against HepG2 and MCF-7 cells, targeting the VEGFR-2 enzyme. Compounds 10, 9, 8, and 15 were found to be the most potent derivatives against the two cancer cell lines,?HepG2 and MCF-7, respectively, with IC50 = 4.25 and 6.08 μM, 4.68 and 11.06 μM, 4.34 and 10.29 μM, and 6.37 and 12.83 μM. Compound 10 displayed higher activity against HepG2 cells than sorafenib (IC50 = 9.18 and 5.47 μM, respectively) and doxorubicin (IC50 = 7.94 and 8.07 μM, respectively). It also showed higher activity than doxorubicin against MCF-7 cells, but lower activity than sorafenib. Compounds 9, 8, and 15 displayed higher activities than sorafenib and doxorubicin against HepG2 cells but exhibited lower activities against MCF-7 cells. Compound 10 potently inhibited VEGFR-2 at an IC50 value of 0.12 μM, which is nearly equipotent to sorafenib (IC50 = 0.10 μM). Compounds 8 and 9 exhibited very good activity with the same IC50 value of 0.13 μM. The six most potent derivatives, 6, 9, 8, 10, 15, and 18, were tested for their cytotoxicity against normal Vero cells. Compounds 6, 8, 9, 10, 15, and 18 are, respectively, 1.13, 3.74, 4.18, 3.64, 2.81, and 2.00 times more toxic to HepG2 and 2.06, 1.58, 1.76, 2.54, 1.40, and 2.69 times more toxic to MCF-7 breast cancer cells than in normal Vero cells.

A convenient synthesis of [1,2,4]triazolo[1,5-a]pyridines and 1,8-naphthyridine of analgesic and anti-inflammatory profiles

Starting from 1,6-diamino-3,5-dicyano-4-aryl-2-pyridones, substituted triazolo[1,5-a]pyridines and 1,8-naphthyridine derivatives have been synthesized. All the synthesized compounds were fully characterized by spectroscopic, physical data, and elemental analyses. Some of triazolo[1,5-a]pyridines were tested with respect to their analgesic and anti-inflammatory activities. All tested compounds exhibited analgesic activities comparable or superior to Valdecoxib. The anti-inflammatory activity was present in all the tested compounds as well and exceeded that of Hydrocortisone.